Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma

Figure 4

Scheme of the treatment indicating the tumor sizes and CRP levels. The time of tumor recurrence was regarded as time zero.